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Abstract
This study aimed to enhance the water solubility and antitumor efficacy of (-)-gossypol. 
Polyethyleneimine conjugated with stearic acid (PgS) was used for loading and protecting (-)-
gossypol through hydrogen bonding. Double-layered hyaluronic acid (HA)-modified PgS 
nanoparticles encapsulating (-)-gossypol [(-)-G-PgSHAs] were prepared through a two-step 
fabrication process. The nanoparticles possessed a uniform spherical shape with a dynamic size of 
110.9 ± 2.4 nm, which was determined through transmission electron microscopy and dynamic 
light scattering analysis. The encapsulation efficiency and drug-loading capacity of (-)-G-PgSHAs 
were 72.6% ± 3.1% and 9.1% ± 0.42%, respectively. The IR spectra of the samples confirmed the 
protection effect of hydrogen bonding on the optical activity of the encapsulated (-)-gossypol. (-)-
G-PgSHAs exhibited a controlled and tumor-specific release because of the high expression of 
HAase in the tumor region. The tumor-targeting feature of PgSHAs due to HA-receptor mediation 
was confirmed by in vitro cell uptake and in vivo near infrared fluorescence imaging. The in vitro 
test showed that the (-)-G-PgSHAs had similar cytotoxicity to free (-)-gossypol and was smaller 
than that of the encapsulated (±)-gossypol [(±)-G-PgSHAs]. The in vivo study of the anti-cancer 
effect of (-)-G-PgSHAs revealed that (-)-G-PgSHAs had a more enhanced tumor-suppression 
effect and reduced systemic toxicity compared with free (-)-gossypol and (±)-G-PgSHAs (P < 
0.05). Therefore, PgSHA was a useful (-)-gossypol nanocarrier that exhibits high biocompatibility, 
tunable release of drug, and tumor-targeting characteristics for cancer treatment. In addition, this 
double-layered nanocarrier provided novel strategies for the encapsulation of other chiral drugs.
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Optical activity is an essential property of chiral drugs. Various chiral drugs have already 
been investigated and used as their racemic mixtures for clinical applications.1, 2 However, 
the two enantiomers of a chiral drug generally have diverse pharmacodynamic, 
pharmacogenetic and pharmacokinetic properties, and one of the enantiomers of the racemic 
drug may be pharmacologically inactive or even toxic.2, 3 Therefore, using the appropriate 
enantiomer of a drug is crucial in clinical therapies. Gossypol, a natural compound 
investigated as a promising anticancer drug, is an important chiral drug. This drug has been 
studied in many clinical trials in its racemic form.4-6 However, as gossypol is water-
insoluble, oral administration is so far still the best treatment for cancer using this drug.
Like many other chiral drugs, notable differences were found in the metabolism between 
(+)- and (-)-gossypol, and only (-)-gossypol has been reported to have significant antitumor 
effect, because of its binding affinity to Bcl-2, Bcl-xL, and Mcl-1 proteins that are rational 
therapeutic targets with pathway regulation functions, leading to tumor cell apoptosis.7-9 
Unfortunately, (-)-gossypol is not stable and can easily racemize in the body, which largely 
reduces its administrated dosage concentration, resulting in unsatisfactory drug efficacy and 
unwanted side-effects. Thus, its poor stability, and low water-solubility, have become the 
major problems in (-)-gossypol treatment. In order to solve these problems, one suitable 
method is the encapsulation of (-)-gossypol using nanocarriers, which increases its water-
solubility for injection (e.g. intravenous injection), protects it from its environment, as well 
as reduces its side-effects by achieving tumor-targeting through the enhanced permeability 
and retention (EPR) effects and/or the incorporation of tumor-targeted moieties. Although 
multiple studies for gossypol antitumor effects and their mechanism have been reported, 
only a few studies on the gossypol nanocarriers are available. Cho et al. reported 
encapsulated gossypol with micelles comprising of PEG-PCl polymers that loaded 
paclitaxel, cyclopamine and gossypol together.10 Zhai et al. prepared gossypol liposomes to 
prove the low gossypol toxicity, but no in vivo study was involved.11 Furthermore, the 
gossypol carrier studies mentioned above only involved the racemic gossypol, which 
consists of both (+)-gossypol and (-)-gossypol.
To date, very few of the nanocarriers can meet the requirements of encapsulating chiral 
drugs. Ideally, nanocarriers for chiral drug should have adequate loading capacity, 
biocompatibility, and more importantly, the ability to protect the drug from racemization 
during the encapsulation in vitro and the delivery in vivo. Gossypol is a polyphenol with two 
naphthalene rings which can relatively rotate on their carbon-carbon bond (Scheme 1A), 
thus forming (+)- and (-)-gossypol. The delivery of (-)-gossypol is limited by the fact that 
the two active aldehyde groups in the (-)-gossypol structure can easily react with the 
surrounding materials in the solution. Once the reaction occurs, relative rotation of its two 
naphthalene rings may happen, resulting in the racemate product, which was observed in our 
previous experiments. Therefore, developing a suitable nanocarrier that encapsulates (-)-
gossypol with a high drug loading efficiency and without racemization is still a challenge for 
the clinical application of (-)-gossypol.
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As shown in Scheme 1A, (-)-gossypol has two naphthalene rings, whose relative rotation 
can lead to racemization of the drug. The chemical structure of (-)-gossypol indicated that, 
proper ‘pins’ are needed within the nanocarrier to restrain it from racemizing. Without such 
‘pins’, the naphthalene rings of the (-)-gossypol can rotate freely. On the contrary, if the 
‘pins’ are too strong, they may change the bioactivity of (-)-gossypol. The double-stranded 
DNA can maintain its secondary structure and bioactivity through hydrogen bonds, which 
suggests that, hydrogen bonds may function as the ‘pins’, because (-)-gossypol has eight 
hydroxyl groups that have the potential to form hydrogen bonds with suitable loading 
materials. Therefore we hypothesized that the hydrogen bonding between (-)-gossypol and 
its nanocarrier could avoid the racemization and keep the bioactivity of (-)-gossypol.
After many investigations, we finally found that PEI could be a good candidate for (-)-
gossypol delivery. PEI is a water-soluble polymer that contains numerous primary, 
secondary, and tertiary amino groups, thus it can form hydrogen bonds with the hydroxyl 
groups of (-)-gossypol. PEI with a high molecular weight has been used to deliver various 
bioactive molecules, such as DNA plasmid, siRNA, and anti-sense oligodeoxynucleotide 
(ODN).12-14 Water-insoluble drugs can be loaded by the micelles, which were formed using 
modulated PEI amphiphilic materials. For example, Yim et al. synthesized amphiphilic PEI-
g-all-trans-retinoic acid (PRA), which could self-assemble into micelles that encapsulate the 
hydrophobic anticancer drug paclitaxel. Furthermore, the cytotoxicity of PRA graft 
conjugates was lower than that of raw PEI, and gradually decreased with increasing PRA 
graft ratios.15
In addition, as a natural polysaccharide found in the extracellular matrix and synovial fluids 
of the body, hyaluronic acid (HA)-based nanoparticles (HA-NPs) as potential carriers of 
anticancer drugs have drawn substantial attention because they can specifically bind to 
various cancer cells that overexpress CD44 (an HA receptor) with high affinity for HA.16, 17 
Some normal cells can also express CD44 at low levels. But CD44 expressed by normal 
cells are usually in a low affinity state that does not have the capacity to bind HA.17 Thus 
HA was widely used as the carrier for the targeting therapy of cancer.18-20
Based on the investigations mentioned above, we designed a novel injectable double-layered 
HA/PEI nanoparticles (NPs) for the delivery of (-)-gossypol. First, a PEI amphiphile, which 
consisted of a low-molecular weight (10 kDa) branched PEI grafted with hydrophobic 
stearic acid (PEI-g-SA, annotated as PgS), was synthesized (Scheme 1B). This amphiphilic 
PEI conjugate could reduce PEI toxicity and easily form micelles that encapsulate (-)-
gossypol during the self-assembly process (Scheme 1C), and it could maintain the optical 
activity of (-)- gossypol. Afterwards, positively charged PgS micelles were covered with a 
shell of negatively charged HA via electrostatic interaction, forming double-layered HA/PEI 
nanoparticles [(-)-G-PgSHAs]. This kind of nanoparticle had the ability to maintain the 
optical activity of (-)-gossypol, low toxicity, and high antitumor therapeutic effect in vitro 
and in vivo, thereby serving as a useful antitumor drug carrier for cancer treatment.
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Cell culture medium [Dulbecco's modified Eagle medium (DMEM)], trypsin (for cell 
culture use, 0.25% w/v), and six-well dishes were purchased from Thermo Fisher Scientific 
Co., Ltd. (Shanghai, China). Fetal bovine serum (FBS) was purchased from Zhejiang 
Tianhang Biological Technology Co., Ltd. The 10 cm cell culture dishes, 96-well plates, and 
other biological experimental consumables were purchased from Corning Co., Ltd. 
Hyaluronidase from bovine testes (HAase, 683.6 units mg-1) and (-)-gossypol with [α]D 
-350° to -365° (c 0.3 in CDCl3) were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA). Branched PEI (MW 10 kDa), stearic acid (SA), N-hydroxysuccinimde (NHS), N, N-
dicyclohexyl-carbodiimide (DCC), HA (MW > 100 kDa, sodium salt), penicillin/
streptomycin, and rhodamine B isothiocyanate (RITC) were purchased from Aladdin 
Chemistry Co., Ltd. (Shanghai, China). Thiazolyl blue tetrazolium bromide (MTT) was 
purchased from Amresco, Inc. (Solon, USA). 1,1-dioctadecyl-3,3,3,3-tetramethylindotri-
carbocyanine iodide (DiR) was purchased from Invitrogen (NY, USA). Other reagents were 
of analytical grade. All chemicals and reagents were used without further purification.
Synthesis of PgS conjugates
We grafted SA to PEI through condensation reaction between the carboxylic acid of SA and 
the amino groups of PEI (Scheme 1B). Three kinds of PgS conjugates with different degrees 
of SA substitution were prepared. SA (0.7 mmol), NHS (0.72 mmol), and DCC (0.72 mmol) 
were dissolved in 30 mL of absolute ethanol and the solution was stirred thoroughly for 30 
min. Then, 10 mL absolute ethanol, containing 0.056, 0.092, and 0.144 mmol PEI was 
added into the above solution respectively, and were mixed and stirred at room temperature 
to start the condensation reaction. After 20 h, the reaction solution was transferred into a 
dialysis membrane of 3500 Da MWCO, and was dialyzed against absolute ethanol for 3 
days during which the medium was routinely replaced with fresh absolute ethanol every 12 
h. Finally, the solvent was evaporated to obtain the PgS conjugates. The degree of SA 
substitution in the three different PgS conjugates (annotated as PgS1, PgS2 and PgS3) was 
then measured using high-performance liquid chromatography (HPLC) analysis system 
(Agilent 1100, U.S.A) equipped with Agilent G1316A capillary pump, Agilent G1316A 
thermostatted column compartment, and Agilent G1315B diode detector. The flow rate of 
mobile phase [methanol/water (92:8, v/v)] was 0.8 mL min-1 at 25 °C. The UV absorbance 
of SA was measured at 225 nm.
The chemical structure of PgS conjugates was verified using 1H nuclear magnetic resonance 
(NMR) and infrared (IR) analysis. 1H NMR spectra were recorded using an Avance NMR 
spectrometer (Bruker Co., Switzerland) operated at 400 MHz. SA was dissolved in 
chloroform-d, and the PgS2 and PEI samples were prepared in methanol-d4. 
Tetramethylsilane was used as the internal standard. The concentration of the three samples 
for 1H NMR analysis was approximately 20 mg mL-1. For the IR analysis, SA, PgS, and PEI 
were co-pressed with potassium bromide (ca. 1.5%, w/w), and then analyzed using a 
Fourier-transform infrared (FTIR) spectrometer (Shimadzu Co., Japan). The transmission 
absorption spectra were obtained in the range of 400 cm-1 to 4000 cm-1.
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Three kinds of amphiphilic PgS conjugates were prepared using hydrophilic PEI and 
hydrophobic SA at different ratios. After our investigation, the PgS2 conjugate (containing 
an average of 6.57 SA molecules per PEI chain) was used for the final preparation of (-)-G-
PgSHAs. As shown in Scheme 1C, the (-)-G-PgSHAs were prepared through a two-step 
process. In the first step, 8 mg PgS2 was dispersed in 80 mL distilled water. Afterwards, 5 
mL ethanol containing 15 mg (-)-gossypol was slowly added into the solution. Stirring was 
continued for 90 min. The (-)-gossypol-loaded PgS micelles were obtained after the mixture 
solution was continuously filtered using a glass funnel. In the second step, 20 mL 0.5% HA 
solution was added dropwise to the (-)-gossypol PgS2 micelle solution, followed by stirring 
for 3 h. This step allowed the binding of HA molecules onto the surface of PgS micelles 
through electrostatic interaction. Excess gossypol molecules were removed through 
extensive dialysis using a buffered solution [phosphate buffer/ethanol (7:3), pH 7.4]. For 
every 4 h, the buffered solution was replaced with an equal volume of fresh medium, and the 
optical absorbance of each solution was measured at 385 nm to determine the free (-)-
gossypol concentration. This process was stopped after 28 h when free (-)-gossypol 
molecules were almost undetectable. The final solution of NPs was freeze-dried to obtain a 
yellow powder of (-)-G-PgSHAs.
Confirmation of hydrogen bonding between PgS and (-)-gossypol
IR analysis was used to study the interactions between the drug molecules and loading 
materials. Free (-)-gossypol, PgS, HA, drug-loaded PgS micelles, and (-)-G-PgSHAs were 
respectively co-pressed with potassium bromide (ca. 1.5%, w/w), and were then analyzed 
using an FTIR Spectrometer (Shimadzu Co., Japan). The transmission absorption spectra 
were obtained in the range of 400 cm-1 to 4000 cm-1.
Characterizations of (-)-G-PgSHAs
The morphology of (-)-G-PgSHAs was observed via transmission electron microscopy 
(TEM) (H-800, Hitachi, Japan). The samples were placed on an ultra-thin carbon support 
film on a copper grid, and observed at different magnifications. In addition, TEM 
photographs with a higher resolution were also taken through another round of TEM 
(JEM-2100F, JEOL, Japan) to observe their core-shell structure. The zeta potential and size 
distribution of (-)-G-PgSHAs were measured by Dynamic Light Scattering (DLS) using a 
Malvern instrument (Nano-ZS90, Malvern, UK).
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where Mgossypol input is the amount of (-)-gossypol input before encapsulation and 
Mgossypol free is the amount (mg) of (-)-gossypol in the filter residue (un-encapsulated). 
MG-PgSHAs is the amount of the prepared (-)-G-PgSHAs (based on total weight of the 
nanoparticles).
Drug-release profiles and stability of (-)-G-PgSHAs
The in vitro drug release profiles were obtained through dynamic dialysis, and the test was 
conducted using a dialysis membrane (MWCO 3500) in 20 mL PBS (pH 7.4) stirred at 25 
rpm. All experiments were performed under sink conditions at 37° ± 0.3 °C using 
lyophilized (-)-G-PgSHAs containing 3 mg (-)-gossypol. The amount of released (-)-
gossypol was determined using a UV-vis spectrophotometer and (-)-gossypol calibration 
curve obtained at 386 nm wavelength. The same amount of (-)-G-PgSHAs with 10 U mL-1 
HAase were dispersed in 20 mL PBS (pH 7.4) and used as the control. The in vitro drug-
release profiles were determined under the same conditions. To investigate the stability of 
(-)-G-PgSHAs, their samples in PBS with a (-)-gossypol concentration of 0.15 mg mL-1 
were restored in a centrifuge tube inside a 4 °C refrigerator. Afterwards, the size distribution 
of the samples was examined at determined intervals.
Cell culture
Prostate cancer cell line PC-3 and CL-1, and myocardium cell line H9C2 were provided by 
the Department of Molecular Biosciences, University of Kansas and by the School of Life 
Science and Technology, Xi'an Jiaotong University. All cell lines were maintained in 
complete DMEM supplemented with 10% (w/w) FBS and penicillin/streptomycin (76 and 
36 U mL-1, respectively). The cells were incubated under 5% CO2 at 37 °C in a cell 
incubator (MCO-18AIC, Sanyo, Japan) before they were used for in vitro tests or mice 
inoculation.
In vitro cytotoxicity and cellular uptake
MTT method was adopted to test the viability of PC-3 and H9C2 (myocardium) cells against 
PgS1 (containing an average of 3.75 SA molecules per PEI chain), PgS2 conjugates 
(containing an average of 6.57 SA molecules per PEI chain), and raw PEI as the control. The 
cells were seeded onto 96-well flat-bottomed plates with 1×105 cells/well density, and were 
incubated under 5% CO2 atmosphere at 37 °C. After 24 h of incubation, the cells were 
washed with PBS. The complete medium containing various concentration of either PgS 
conjugates or PEI was added to each well. After 72 h, the medium was replaced with a fresh 
batch, and then 20 μL of MTT solution (5 mg mL-1) was added to each well. The cells were 
then incubated for an additional 4 h under the same conditions. The medium with MTT was 
removed, and 100 μL dimethyl sulfoxide (DMSO) was added to each well. The absorbance 
was measured at 590 nm using an ELISA plate reader (Infinite® 200 Pro, Tecan, 
Switzerland).
To study the cytotoxicity of (-)-G-PgSHAs as a tumor-targeted nanomedicine and compare 
it with the racemic gossypol-loaded PgSHAs [(±)-G-PgSHAs], the in vitro cytotoxicity of 
(-)-G-PgSHAs (with a DLC of 9.6%), (±)-G-PgSHAs, free (-)-gossypol, and racemic 
gossypol [(±)-gossypol] against PC-3 and CL-1 cells, was measured using the MTT assay 
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explained above. The maximal concentration of (-)-G-PgSHAs used was 0.865 mg mL-1 
[containing 0.083 mg mL-1 (-)-gossypol and about 0.06 mg mL-1 PgS]. PgS samples with 
0.06 mg mL-1 PgS were used to treat cells for comparison.
To confirm the CD44-mediated endocytosis of the HA-shielded nanocarrier, the cellular 
uptake behavior of PgSHAs was observed using a fluorescent microscope and a confocal 
laser scanning microscope (CLSM). Drug-free PgSHAs were labeled with RITC. PC-3 cells 
attached to 6-well plates were treated with RITC-labeled PgSHAs (containing 50 μg mL-1 
PgS) with or without 1% HA. After incubation in the dark for a predetermined time, the 
cells were rinsed twice with PBS (pH 7.4), and were then visualized using an inverted 
fluorescence microscope (Eclipse Ti-S, Nikon, Japan). For confocal microscopy, PC-3 cells 
attached to 6-well plates covered with coverglass were treated with the samples as described 
above. After incubation in the dark for a predetermined time, the cells were rinsed with PBS 
and fixed using 4% paraformaldehyde solution. The nuclei of the cells were stained using 
1μg mL-1 DAPI. The coverglass was then transferred onto the slide glass, followed by the 
observation using a CLSM (TCS SP5 II, Leica, Germany).
Animal tumor models
All animal experiments were done in compliance with the Guidelines for Use and Care of 
Animals in the University of Kansas. NOD.CB17-Prkdcscid (SCID) mice were from our own 
mice colony and NCI athymic NCr-nude mice were purchased from Harlan Laboratories. 
The mice were fed in a standard housing condition until 6 weeks of age and with 20 g to 25 
g body weight.
To establish tumor models, 200 μL DMEM containing 1 × 106 cells (PC-3 or CL-1) were 
s.q. injected in the SCID or nude mice, using a sterile 23-gauge needle. Tumors were grown 
to predetermined sizes before the mice were used for the in vivo fluorescence imaging or 
drug efficacy studies.
In vivo distribution of PgSHA nanoparticles
The in vivo tumor-targeting of PgSHAs was confirmed using DiR, which is a near infrared 
(NIR) fluorescent dye. Four SCID mice bearing bilateral CL-1 tumors were used. Two mice 
were iv. injected with 200 μL DiR-loaded PgSHA nanoparticles, and another two mice were 
iv. injected with 200 μL DiR ethanol/water (1:4 v/v) solution as the control. The DiR 
concentration was 50 μmol L-1 in both groups. At different time points, the biodistributions 
of free DiR or DiR-loaded PgSHA nanoparticles in the four mice were imaged using a 
Carestream Molecular Imaging System (Carestream Health, Inc), with excitation at 750 nm 
and emission at 790 nm using exposure time of 60 s. All mice were euthanized by 
overdosing with CO2 at 96 h after the injections. The organs and tumors of mice were 
extracted for ex vivo imaging. In addition, the distributions of the free DiR or DiR-loaded 
PgSHA nanoparticles were quantified by measuring the signal intensity at the region of 
interest.
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In vivo tumor suppression effect of (-)-G-PgSHAs
Prostate cancer (PC-3) model was used to investigate the tumor suppression effect of (-)-G-
PgSHAs. PC-3 cells were s.q. inoculated on the back of nude mice. When the tumors 
reached an average size of 50 mm3, the mice were randomly divided into five groups (n = 8) 
given as follows: (1) delivering PBS (blank control); (2) blank PgSHAs (vehicle control); 
(3) (-)-G-PgSHAs at 10 mg (-)-gossypol kg-1; (4) free (-)-gossypol at 10 mg kg-1, for which 
a 100 mg mL-1 (-)-gossypol in DMSO was diluted with PBS on the day of treatment; and (5) 
(±)-G-PgSHAs at 10 mg (±)-gossypol kg-1. Each group was iv. injected twice a week for 
three weeks. The tumor sizes and body weight of each mouse were measured twice a week, 
and tumor volumes were calculated as a×b2/2, where a and b represented the longest and 
shortest diameters of the tumor, respectively. After 30 d, all animals were sacrificed. The 
tumor tissues and other tissue samples, such as the heart, kidney, liver and lung, were 
removed. The sections of tumors and organs were stained with hematoxylin and eosin, and 
their histology was then studied and compared.
Statistical analysis
The data on tumor growth were reported as mean ± SEM, and were analyzed using two-way 
ANOVA. The data of in vitro drug release, cytotoxicity, and ex vivo imaging were reported 
as mean ± SD, and were analyzed using one-way ANOVA or Student's t-test to determine 
the difference among the samples. The data analysis was done using Prism 5.0 software 
(GraphPad Prism, CA, USA). P values < 0.05 were considered as statistically significant.
Results and discussion
Synthesis and characterization of PgS conjugates
Gossypol is a promising anticancer drug, which has been studied in many clinical trials in its 
racemic form.4-6 To date, almost no nanocarrier has been reported for (-)-gossypol, which is 
unstable and easily racemizes during the encapsulation in vitro and/or the delivery in vivo. 
Based on the chemical structure of (-)-gossypol, we hypothesized that, the formation of 
hydrogen bonds between (-)-gossypol and its loading material could prevent the 
racemization and maintain the bioactivity of (-)-gossypol. After our investigations, we found 
that PEI adequately protects (-)-gossypol through hydrogen bonding because of its intensive 
amino groups. PEI has long been investigated as an effective gene carrier and has been 
widely used to condense antisense ODN, pDNA, and siRNA.12-14 As gene carrier, the 
commonly used PEI with high molecular weight (25 kDa) possesses evident cytotoxicity, 
whereas PEI with low molecular weight has lower toxicity. However, the transfection 
efficiency of the latter is relatively weaker.21, 22 Therefore, PEI with low molecular weight 
is a potential material for drug delivery. However, as (-)-gossypol is hydrophobic, PEI needs 
to be modulated into an amphiphilic material for the encapsulation of (-)-gossypol. By 
contrast, stearic acid (SA) is a hydrophobic saturated fatty acid and has been used as a safe 
biodegradable dietary additive. SA can be grafted to low molecular weight PEI because of 
its good biosafety and suitable molecular weight. As a result, a new amphiphilic PEI-g-SA 
conjugate (PgS) was prepared through condensation reaction between the carboxyl acid of 
SA and the amino groups of PEI. Three kinds of PgS conjugates with different SA 
substitution degrees were prepared by changing the amount of PEI. The mole ratios of SA to 
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PEI in three PgS conjugates were 11.81, 6.57, and 3.75 as determined using HPLC and 1H 
NMR, which means 11.81, 6.57, and 3.75 SA molecules on average were grafted to the PEI 
chain for each kind of PgS conjugate. These conjugates ranged from colorless viscous liquid 
to yellowish sticky solid with increasing SA contents.
The IR and 1H NMR analysis confirmed the successful synthesis of PgS. Fig. 1A shows the 
IR spectra of SA, PgS, and PEI. The IR spectra of PgS, compared with that of PEI, showed 
additional peaks at 1636 and 1410 cm-1. This finding indicated newly formed amide bonds 
(–NHCO-). With increased SA content in the PgS conjugates, the peak intensity of the 
amide bonds increased significantly, whereas the intensity of amine peaks from 3300 cm-1 
to 3350 cm-1 became relatively weaker. Moreover, SA peaks at 1703 and 943 cm-1 that 
characterize carboxylic acid (–COOH) did not appear in the spectra of PgS conjugates. This 
result demonstrated the condensation reaction between the carboxyl acid of SA and the 
primary amines on PEI molecule chains. Moreover, 1H NMR was used to confirm that SA 
was introduced into the PEI backbone, as shown in Fig. 1B. Except for the reference and 
ethanol residue, all peaks were annotated. Detailed analysis of 1H NMR spectra is as 
follows: PEI (δ = 2.6 ppm to 2.8 ppm (A) for H in –NCH2CH2N–), PgS (δ = 2.6 ppm to 2.8 
ppm (a) for H in –NCH2CH2N–;δ = 2.15 ppm (b) for H in –COCH2–; δ = 1.6 ppm (c) for H 
in –CH2–; δ = 1.3 ppm (d) for H in –(CH2)14–; δ = 0.9 ppm (e) for H in –CH3), SA (δ = 2.30 
ppm to 2.35 ppm (B) for H in –COCH2–; δ = 1.61 ppm to 1.65 ppm (C) for H in –CH2–; δ = 
1.26 ppm to 1.30 ppm (D) for H in –(CH2)14–; δ = 0.9 ppm (E) for H in –CH3). In summary, 
PgS had the distinctive peaks of both SA and PEI. The slight differences between the 
chemical shifts of peak b and B, as well as peak c and C, were mainly caused by the change 
of chemical environment of hydrogen atom. Thus, all the facts mentioned above 
demonstrated that the PgS conjugates were produced through condensation reaction between 
the carboxyl acid of SA and the primary amines on PEI chains.
Cytotoxicity of PgS conjugates
Positively charged PEI can cause cytotoxicity because of its interaction with cell 
membranes.23 As a PEI derivative, PgS conjugates could also cause cytotoxicity when used 
as drug carriers. Therefore, we evaluated the cytotoxicity of PgS conjugates against PC-3 
(prostate cancer cell line) and H9C2 (myocardium cell line) cells using MTT assay. As 
shown in Fig. 2A and 2B, the cytotoxicity of PgS conjugates was lower than that of PEI. In 
addition, the cytotoxicity became much lower with increasing SA contents in PgS. Under the 
experimental conditions mentioned above, the IC50 values of PEI against PC-3 and H9C2 
cells were determined to be approximately 30 and 42 μg mL-1, respectively. The apparent 
IC50 values against PC-3 and H9C2 were about 79 and 72 μg mL-1, respectively, for PgS1, 
and about 94 and 93 μg mL-1, respectively, for PgS2. The results of MTT assay indicated 
that the cytotoxicity of PgS conjugates decreased with increasing SA contents in PgS, which 
is ascribed to the nontoxic SA portion in PgS. However, PgS also became stickier and had 
poorer water solubility when the SA content in PgS was very high. Therefore, for the 
subsequent drug encapsulation, we used PgS2 with a moderate SA substitution degree, 
which had a relatively low cytotoxicity but also possessed good amphiphilicity and water 
solubility.
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The micelles formed by PgS2 conjugate were used to encapsulate (-)-gossypol. Fig. 3 shows 
that, the IR absorption peak of (-)-gossypol at 1283 cm-1, which characterizes the phenolic 
hydroxyl groups, redshifted to 1247 cm-1 when the drug was encapsulated in PgS micelles, 
which indicated the formation of hydrogen bonds between the phenolic hydroxyl groups of 
(-)-gossypol and the amino groups of PgS. On the other hand, the peak of (-)-gossypol at 
1616 cm-1, which characterizes the aldehyde groups, exhibited a slight shift after the 
encapsulation, suggesting that the aldehyde groups in (-)-gossypol were protected by PgS 
micelles and were kept intact.
Although a relatively lower cytotoxicity was obtained when SA was grafted to PEI, tumor 
targeting was necessary to further reduce the toxicity and enhance the drug efficacy of 
chemotherapy. As a result, tumor-targeting material HA was adapted to shield the (-)-
gossypol-loaded PgS micelles via electrostatic interaction. As tumor-targeting materials, HA 
and its derivatives have been used in the delivery of many pharmaceutics, including 
nucleotide therapeutics, protein and peptide therapeutics, and some small molecular drugs.24 
HA have many excellent biochemical characteristics, such as biocompatibility, 
biodegradability and non-cytotoxicity.25 HA can also helps pharmaceutics into the 
intracellular matrix by forming complexes with HA receptors, which are commonly over-
expressed in many tumor cells, followed by HA receptor-mediated endocytosis. Therefore, 
we prepared (-)-gossypol-loaded nanoparticles with intact HA outer layer [(-)-G-PgSHAs]. 
In Fig. 3, the IR absorption peak of HA at 1037, 1401, and 1618 cm-1 characterizing the 
hydroxyl groups, carboxylates, and amide bonds, respectively, also appeared in the spectrum 
of (-)-G-PgSHAs, indicating that the (-)-gossypol-loaded PgS micelles were shielded by HA.
Characterization of (-)-G-PgSHAs
Fig. 4A and 4B are the TEM images of (-)-G-PgSHAs at different magnifications. The 
nanoparticles exhibited uniform particle size and spherical shape with a clear core-shell 
structure. The particle size looked slightly smaller compared with the results obtained by 
DLS (Fig. 4C), which was probably due to the elimination of the solvent (i.e. water) around 
the nanoparticles when the sample was observed using TEM. The zeta potential of (-)-G-
PgSHAs was approximately -30 mV (Table 1). The size distribution and zeta potential of 
drug-free PgS micelles and PgSHAs were also measured for comparison. The size of PgS 
micelles increased after being shielded with HA. The zeta potential of PgS micelles was 
changed from +22.8 ± 3.5 mV to –27.4 ± 2.7 mV after the covering of negatively charged 
HA. When loading (-)-gossypol, (-)-G-PgSHAs had a much larger particle size, and their 
negative charge was more notable, which may be attributed to the slightly negative charge of 
(-)-gossypol. In addition, the size and zeta potential of (-)-G-PgSHAs were not significantly 
different from those of (±)-G-PgSHAs. After storage at 4 °C and at room temperature for 6 
months, only negligible differences in the (-)-G-PgSHAs were observed in terms of 
morphology and particle size, and the encapsulated (-)-gossypol was still maintained in its 
levorotatory form (data not shown), indicating a good stability of (-)-G-PgSHAs.
The DLC and EE values of (-)-G-PgSHAs were 9.1% ± 0.42% and 72.6% ± 3.1%, 
respectively. The leakage or burst release of drug, which is a common phenomenon for most 
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nanocarriers, is another problem solved by this delivery system. The in vitro release profile 
of (-)-gossypol from (-)-G-PgSHAs was investigated in PBS using dialysis diffusion 
technique. Fig. 4D shows the release profile of free drug, drug-loaded PgS micelles [(-)-G-
PgS], (-)-G-PgSHAs, and (-)-G-PgSHAs with 10 U mL-1 HAase. Free (-)-gossypol 
molecules dispersed rapidly from dialysis membrane into the outer PBS. The dispersion of 
free drug was balanced within 2 days when 85% (-)-gossypol was released. In contrast, only 
a small amount of (-)-gossypol (about 2%) in (-)-G-PgSHAs was released into the outer 
phase even after a week. When HAase was added, the (-)-gossypol-loaded PgS micelles 
were gradually released as the HA layer was degraded. As a result, (-)-G-PgSHAs with 
HAase demonstrated a faster release of (-)-gossypol, similar to that of (-)-G-PgS. As many 
tumor tissues have much higher HAase concentration than normal tissues,26 the findings 
above indicated that (-)-G-PgSHAs may possess a tumor-specific release of (-)-gossypol in 
vivo, leading to a higher cytotoxicity of (-)-gossypol in tumor tissues than in normal tissues. 
However, only 43% of the total (-)-gossypol was released after 8 days, which may be 
ascribed not only to the hydrophobic interaction but also to the electrostatic interaction 
between PgS and (-)-gossypol, because (-)-gossypol molecules were slightly negatively 
charged at pH 7.4 based on our previous observation.
To study the potential of (-)-G-PgSHAs as an anti-cancer formulation, their cytotoxicity 
against CL-1 and PC-3 prostate cancer cells was evaluated using MTT assay. For both cell 
lines, the IC50 values of encapsulated (-)-gossypol were similar to those of free (-)-gossypol, 
and were almost half of those of encapsulated (±)-gossypol (Fig. 5A and 5B). These results 
indicated that the encapsulated (-)-gossypol was protected from racemization, and its drug 
efficacy was still maintained after the encapsulation. As PgS conjugates also exhibited 
cytotoxicity, although much less than that of PEI, we investigated the effect of drug-free 
PgSHAs on the same cell lines. Under the same MTT experiment conditions, the drug-free 
PgSHAs containing 0.06 mg mL-1 PgS (equal to the PgS content of (-)-G-PgSHAs in the 
maximum concentration group) was used to treat the cells. As a result, the cell viability was 
86.5% ± 2.7% for PC-3 and 75.6% ± 4.1% for CL-1, which indicated that the PgSHA 
portion certainly contributed to (-)-G-PgSHAs cytotoxicity. However, its effect may be 
significantly smaller than the drug itself.
In vitro cellular uptake of PgSHAs
The tumor-specific delivery of PgSHAs was studied both in vitro and in vivo. Initially, 
cellular uptake behavior of PgSHAs was observed using fluorescent microscopy. PC-3 cells 
were incubated with RITC-labeled PgSHAs with or without 1% HA. Fig. 6 and S1† show 
the cellular uptake profiles after incubation for different time periods. Evident fluorescence 
was observed in cells treated with RITC-labeled PgSHAs after 50 min incubation, and 
became much clearer after 100 min. Most of the PgSHAs seemed to have dispersed in the 
cytoplasm of some cells. By contrast, very few fluorescence blots were observed even after 
100 min when extra 1% HA was added, indicating that free HA molecules competed with 
the HA-shielded PgSHAs in the cellular uptake, which suggested that the cellular 
internalization of PgSHAs was dependant on HA receptor-mediated endocytosis.
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In vivo distribution of PgSHAs
The in vivo tumor-targeting of PgSHAs was studied using near infrared (NIR) fluorescence 
imaging. CL-1 tumor-bearing mice were treated with the same amount of free DiR (control 
group) or DiR formulated in PgSHAs (test group). Fig. 7 shows the in vivo NIR fluorescence 
images of mice at different time after the injection. Apparent fluorescence signal was 
observed 6 h after the injection in the tumors of mouse 1 and 2 (Ms#1 and Ms#2), which 
were given DiR-loaded PgSHAs. The signal remained strong throughout the experiment. For 
the free DiR group, the fluorescence intensity decreased rapidly in the control mice within 
0.5 h after the injection (Fig. 7 and S2†), indicating a rapid clearance and fluorescent 
instability of free DiR in the body. Considerable DiR signal was also observed around the 
livers of test group, which may have been caused by the expression of HA receptor in the 
liver that also substantially binds to HA.27, 28 Some fluorescence could also be seen at the 
extremities and the tongue areas of the mice. This was due to their licking and touching of 
the urine that contained the eliminated dye, which was confirmed by the extraction of DiR 
from the surface of the extremities and the tongue using chloroform (data not shown).
To investigate the biodistribution of DiR-loaded PgSHAs, ex vivo NIRF images of tumors 
and organs harvested 96 h after the injection were obtained (Fig. S3†). In all four mice, DiR 
signals in the liver, lung, and spleen were stronger than those in other organs. In addition, as 
a result of faster elimination of free DiR molecules, DiR signal in the control group was 
weaker than that in the test group. However, compared with the control group, DiR in the 
test group also tended to accumulate in tumors other than the liver, lung, and spleen. In order 
to better compare the two groups, we quantified the tumors/liver and tumor/spleen ratios of 
DiR signal intensity of each mouse, and found that both ratios in the test group were 
significantly higher than those of control group (Fig. S4†). The results above suggested that 
PgSHAs could facilitate their payload into tumors and prolong its retention in the body, and 
therefore may enhance the efficacy of loaded anticancer drugs and reduce the systemic 
toxicity.
In vivo tumor suppression effect of (-)-G-PgSHAs
PC-3 tumor-bearing mice were used to investigate the tumor suppression effect of (-)-G-
PgSHAs. Fig. 8A shows that, within the investigated dose schedule of each treatment, 
tumors in both blank control and vehicle control groups showed rapid growth as a function 
of time, whereas the tumors in the free (-)-gossypol, (-)-G-PgSHA, and (±)-G-PgSHAs 
groups showed a significantly slower growth (P < 0.001, compared with blank control 
group), indicating a effective tumor suppression of each treatments. The body weight of 
mice in free (-)-gossypol was significantly decreased, as expected (Fig. 8B). The systemic 
toxicity of free drug was supposed to be mainly caused by non-specific biodistribution. On 
the contrary, the tumor-targeted PgSHA nanoparticles weakened the systemic toxicity of the 
drug and improved the tumor inhibition. Moreover, the tumor growth in (-)-G-PgSHAs 
group was significantly slower than that of (±)-G-PgSHAs group (P < 0.05), suggesting that 
(-)-gossypol in the nanocarrier kept levorotatory in the body and maintained its bioactivity, 
thus showing a better tumor suppression effect.
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The pathological section images of the tumor and liver tissues agreed with the in vivo 
results. Tumor tissues in free (-)-gossypol, (-)-G-PgSHAs, and (±)-G-PgSHAs groups 
showed notable necrosis, with the smallest amount of tumor cells found in the (-)-G-
PgSHAs-treated group, indicating an excellent therapeutic effect of (-)-G-PgSHAs (Fig. 8C). 
In addition, according to the NIRF imaging, the DiR fluorescence was also observed in the 
liver region of the mouse, which indicated that some of the nanoparticles also accumulated 
in the liver. Therefore the repeated long-term treatment with gossypol may also cause 
damages to the liver.29, 30 In this study, the liver tissues in (-)-G-PgSHAs and (±)-G-
PgSHAs groups exhibited less damage than that in the free (-)-gossypol group (Fig. 8C), 
which demonstrated a low toxicity of drug brought about by the tumor-targeted PgSHA 
nanocarrier with good biocompatibility.
In summary, the PgSHA is an excellent nanocarrier for the chiral drug (-)-gossypol. The 
optical activity of (-)-gossypol was protected by PgSHAs through hydrogen bonding in vitro 
and in vivo, which was proven by the IR analysis, stability studies, MTT experiments, and in 
vivo anticancer efficacy studies.
Conclusions
We designed and prepared a novel double-layered PgSHA nanoparticle encapsulating the 
chiral drug (-)-gossypol through a two-step fabrication process. The nanoparticle can easily 
disperse in water, and has great potential for therapeutic applications because of its 
substantial tumor-targeting ability, sustained release profile, and evident tumor-inhibition 
effects. Moreover, this bilayered nanocarrier may also provide an applicable strategy for the 
encapsulation of other chiral drugs.
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Confirmation of PgS synthesis. (A) IR spectra of SA, PgS and PEI. Samples were co-
pressed with potassium bromide respectively, followed by measurement using FTIR 
Spectrometer; (B) 1H NMR spectra of SA, PgS2 and PEI. SA was dissolved in chloroform-
d, while PgS2 and PEI were prepared in methanol-d4. Tetramethylsilane was used as the 
internal standard.
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The viability of (A) H9C2 and (B) PC-3 cells treated with PEI, PgS1 and PgS2 indicated 
that, with increasing content of non-toxic SA portion, PgS conjugate showed less 
cytotoxicity. Data are presented as mean ± SD (n=3).
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IR spectra of free drug, PgS, drug-loaded PgS micelles [(-)-G-PgS], (-)-G-PgSHA, and HA. 
Samples were co-pressed with potassium bromide respectively, followed by measurement 
using FTIR Spectrometer.
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(A, B) TEM images of (-)-G-PgSHAs with different magnification; (C) In vitro release 
profile of gossypol from (-)-G-PgSHAs with or without HAase (10U mL-1) in PBS at 37 °C. 
Free (-)-gossypol and (-)-gossypol-loaded PgS micelles [(-)-G-PgS] were used for 
comparison; (D) Size distribution of G-PgSHAs measured using Malvern Nano-zs 90.
Liu et al. Page 18














The viability of (A) CL-1 and (B) PC-3 cells treated with free (-)-gossypol, free (±)-
gossypol, (-)-G-PgSHAs and (±)-G-PgSHAs indicated that, the encapsulated (-)-gossypol 
was protected from racemization by PgSHAs and possessed a similar activity to free (-)-
gossypol. Data are presented as mean ± SD (n=3).
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Fluorescence microscopic images showing cellular uptake profile of PgSHAs. PC-3 cells 
attached to 6-well plates were treated with RITC-labeled PgSHAs with or without 1% HA. 
After incubation for different time, cells uptaking the PgSHAs were visualized with fixed 
excitation wavelength, light intensity and exposure time.
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In vivo NIR fluorescence images of CL-1 tumor-bearing SCID mice at different time after 
i.v. injection of DiR-loaded PgSHAs. The sites of tumors are indicated by arrows. Free DiR 
dissolved in ethanol solution was used as the control.
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(A) In vivo tumor growth curves. Nude mice were inoculated s.q. with PC-3 cells on the 
back. Error bars represent SEM. *P < 0.05 [(-)-G-PgSHAs vs. (±) -G-PgSHAs] and ***P < 
0.001 (each treatment vs. PBS), n=8. (B) Body weight of PC-3 tumor-bearing mice receiving 
various treatments. Error bars represent SD, n=8. ***P < 0.001 as compared with original 
body weight. (C) Pathological section images of the tumor (upper row) and liver (lower row) 
tissues of PC-3 tumor-bearing nude mice treated by PBS, free (-)-gossypol, (±)-G-PgSHAs 
and (-)-G-PgSHAs, respectively. All the samples were hematoxylin and eosin stained. 
Magnification was 200×.
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(A) Chemical structure of (-)-gossypol. (B) Chemical reaction equation of PgS synthesis; 
(C) Schematic representation of the fabrication process of (-)-G-PgSHAs.
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Table 1
Summary of diameters and Zeta-potentials of different nanoparticles.a
Nanoparticles Diameters (nm) Zeta potential (mV)





Data are presented as mean ± SD, n=3.
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